GHK-Cu (Copper Peptide): Comprehensive Research Guide — Wound Healing, Skin, Gene Expression and Anti-Aging Data

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II) complex) is the copper chelate of the tripeptide GHK (Gly-His-Lys). The peptide moiety was first isolated from human plasma albumin in 1973 by biochemist Loren Pickart at the University of Minnesota, who observed that a low-molecular-weight fraction of young human serum stimulated liver cell protein synthesis — an activity later attributed to GHK.

GHK exists endogenously as a free tripeptide produced by proteolytic cleavage of larger proteins (albumin, collagen fragments, other ECM proteins). It has high affinity for copper(II) ions (Kd ~10⁻¹⁵ M), forming a stable square planar complex through the alpha-amino group of glycine, the imidazole nitrogen of histidine, and the terminal amino group of lysine. This copper complex is the biologically active form.

GHK-Cu at a glanceStructure: Gly-His-Lys tripeptide:Cu(II) · MW: ~341 Da (peptide), ~404 Da (copper complex) · Discovery: Loren Pickart, 1973 · Endogenous source: proteolysis of serum albumin and ECM proteins · Plasma concentration: ~200 ng/mL in young adults, declining markedly with age

In 1973, Loren Pickart was studying human plasma fractions' effect on liver cell cultures. Young plasma stimulated liver cell activity; aged plasma did not. Fractionation identified the active factor as GHK — present at approximately 200 ng/mL in young plasma but declining to ~80 ng/mL by age 60.

This age-related decline became a central hypothesis: if GHK is a repair-stimulating signal that declines with age, exogenous administration might partially restore repair capacity. This hypothesis drove decades of skin, wound healing, and gene expression research.

GHK-Cu exerts biological effects through multiple converging mechanisms:

Copper delivery and SOD activity: GHK-Cu can transfer copper to copper-zinc superoxide dismutase (Cu/Zn-SOD, SOD1) — the primary cytoplasmic antioxidant enzyme — enhancing the cell's capacity to neutralise superoxide radicals.

Lysyl oxidase (LOX) activation: LOX is a copper-dependent enzyme responsible for crosslinking collagen and elastin fibres in the ECM. GHK-Cu promotes LOX activity, enhancing the functional quality (not just quantity) of newly deposited collagen.

Growth factor receptor modulation: GHK-Cu upregulates FGF receptor and EGF receptor family expression, amplifying cellular responsiveness to endogenous growth signals in wound environments — receptor sensitisation rather than direct growth factor mimicry.

TGF-β modulation: GHK-Cu promotes wound-phase TGF-β signalling (pro-repair) while attenuating fibrosis-associated TGF-β activation. This dual modulation explains why GHK-Cu-treated wounds heal faster with less hypertrophic scarring.

NFκB suppression: Downregulates NFκB-driven inflammatory gene expression, reducing IL-1β, IL-6, and TNF-α production — central to its wound healing benefit since uncontrolled inflammation delays tissue repair.

GHK-Cu has one of the most replicated wound healing evidence bases in the peptide literature, spanning five decades:

• Full-thickness excisional wounds — rodent models consistently show faster wound closure, improved granulation tissue formation, and increased collagen density in GHK-Cu-treated wounds vs controls. Diabetic wound models show particular benefit, with GHK-Cu significantly improving the attenuated healing seen in diabetic subjects.
• Angiogenesis — increased blood vessel density at healing sites via FGF-2 upregulation and endothelial cell activation — a mechanism distinct from VEGF-driven angiogenesis.
• Burn wounds — accelerated epithelialisation and reduced scar formation. Anti-fibrotic TGF-β modulation reduces contracture and hypertrophic scarring.
• Corneal epithelial healing — early Tβ4 competitor work demonstrated topical GHK-Cu accelerates corneal wound closure in animal models.
• Periodontal models — enhanced alveolar bone repair and gingival fibroblast activity, suggesting applications in dental wound healing research.

GHK-Cu's most commercially applied research area is skin biology — collagen synthesis, skin thickness, and photoageing reversal:

Collagen synthesis: GHK-Cu stimulates type I, III, and IV collagen synthesis in fibroblast cultures, with dose-dependent increases across multiple independent in vitro studies. Type I collagen is the primary structural collagen of the dermis; type IV is a major basement membrane component. Both decline with photoageing. Topical application in full-thickness and ex vivo skin models confirms in vitro findings.

Elastin and fibronectin: GHK-Cu promotes elastin synthesis and assembly in fibroblast models. Declining elastin content is a primary cause of skin sagging with ageing. Fibronectin upregulation contributes to improved wound scaffold quality.

Glycosaminoglycans (GAGs): GHK-Cu increases dermatan sulphate and other GAG production in skin fibroblasts. GAGs are the hydrophilic ECM components contributing to skin hydration and turgor.

Photoageing reversal: UV-aged fibroblast cultures and UV-exposed rodent skin models show GHK-Cu can partially reverse photoageing markers: increased collagen content, improved fibroblast morphology, reduced MMP expression upregulated by UV exposure.

GHK-Cu has an established research profile in hair biology:

• Hair follicle size and anagen duration — in vitro hair follicle cultures demonstrated GHK-Cu enlarges follicle size and prolongs the anagen (active growth) phase via FGF-7/KGF upregulation — a key dermal papilla-derived signal for follicle activation.
• Murine models — topical GHK-Cu in mouse dorsal skin accelerated transition from telogen (resting) to anagen (active) phase, increased hair density, and produced thicker hair shafts vs control areas.
• Vascular supply — FGF-2 and FGF-7-driven angiogenesis in the dermal papilla region improves follicle nutrient supply — a putative mechanism for the growth-promoting effect.
• Anti-inflammatory scalp models — NFκB suppression and cytokine reduction may independently preserve follicle health under inflammatory conditions, a major contributor to follicle miniaturisation.

GHK-Cu's antioxidant properties operate through multiple mechanisms:

• SOD1 cofactor supply — copper delivery to Cu/Zn-SOD enhances superoxide radical neutralisation, protecting cellular proteins, lipids, and DNA from oxidative damage
• Iron sequestration — GHK-Cu chelates free iron (Fe²⁺), reducing Fenton reaction-mediated hydroxyl radical production — an antioxidant mechanism distinct from SOD activity
• Carbonyl protein clearance — promotes proteasomal clearance of oxidatively damaged proteins by upregulating proteasome subunit expression — a molecular housekeeping function relevant to cellular ageing models
• NFκB suppression — documented in skin fibroblast and macrophage cultures, reducing the pro-inflammatory cytokine cascade that drives both acute tissue damage and chronic low-grade inflammation

Perhaps the most striking finding in GHK-Cu research is its broad-spectrum effect on gene expression. A 2010 analysis by Pickart and colleagues examining GHK on human gene expression microarrays identified approximately 4,000 genes whose expression was modulated — representing approximately 14% of the human genome's protein-coding genes.

The analysis showed GHK treatment produced:

• Upregulation: ECM repair genes (collagen, fibronectin, laminin), antioxidant defence (SOD1, catalase, glutathione peroxidase), ubiquitin-proteasome pathway, nervous system development, anti-cancer defence mechanisms
• Downregulation: Inflammation (NFκB targets, cytokines), cancer progression (oncogene expression, cell cycle dysregulation), metastasis (MMP expression), apoptosis-inducing pathways

Context on the 4,000 gene findingThis derives from microarray gene expression analysis measuring mRNA transcript levels — not protein activity. mRNA upregulation does not guarantee proportional protein production or functional change. The finding identifies GHK as a broad regulatory signal rather than a specific receptor agonist, consistent with its role as an endogenous damage signal. Functional significance of many expression changes requires further investigation.

Cancer-relevant findings: The gene expression data identified GHK as potentially downregulating genes associated with cancer progression. Independent studies showed inhibition of fibrosarcoma and melanoma cell invasiveness in Matrigel assays, and downregulation of MMP-1 and MMP-2 in melanoma cells. These are preclinical findings only; GHK-Cu has no established anti-cancer application.

RetaLABS GHK-Cu is supplied as lyophilised powder.

• Add bacteriostatic water slowly along the vial wall; gently swirl until dissolved — do not shake. The solution will appear blue-green — this is normal and expected for the copper complex.
• Typical concentration: 0.5–2mg/mL
• Store lyophilised at −20°C, protected from light
• Reconstituted: 2–8°C, use within 4 weeks. Avoid alkaline conditions (pH >8) which can destabilise the copper-peptide complex.

See the Peptide Reconstitution & Storage Guide for general protocol notes.

Why does GHK-Cu solution appear blue or green?

The blue-green colour is characteristic of copper(II) in square planar coordination — absorbing in the red/orange range of visible light. This colouration confirms the copper chelation is intact. A colourless GHK solution would indicate unchelated peptide (GHK without copper) rather than the active GHK-Cu complex.

What is the significance of the age-related decline in GHK?

GHK plasma concentrations decline from approximately 200 ng/mL at age 20–30 to below 80 ng/mL by age 60+. This decline parallels reductions in tissue repair speed, collagen content, and skin quality. The hypothesis is that GHK functions as a repair-activating damage signal whose age-related decline contributes to reduced repair capacity — though causality is not established by correlation alone.

What does the 4,000 gene expression finding mean practically?

GHK functions as a broad regulatory signal — upregulating repair and antioxidant pathways, downregulating inflammatory and cancer-progression pathways — affecting approximately 14% of human protein-coding genes. It makes GHK-Cu a useful research tool for studying coordinated gene expression responses to tissue damage signals. Note: gene expression changes (mRNA) do not guarantee equivalent protein changes or functional outcomes.

Is GHK-Cu the same as "copper peptide" used in skincare?

Yes — GHK-Cu is the "copper peptide" in skin and hair care research. Research-grade GHK-Cu for laboratory research is the same compound, supplied at higher purity with analytical documentation (COA) not required for cosmetic applications.

Is GHK-Cu available in Australia for research?

Research-grade GHK-Cu is available in Australia for laboratory research purposes. RetaLABS stocks research-grade GHK-Cu with COA documentation. All products are for laboratory research use only.

RetaLABS GHK-Cu is sourced from manufacturers providing a Certificate of Analysis (COA) with each batch, covering compound identity, HPLC purity, copper content confirmation, and lot-specific analytical results.

For complementary tissue repair research, see the BPC-157 Research Guide and TB-500 Research Guide. For anti-aging research, see the Epitalon Research Guide. For the Australian regulatory framework, see the Research Peptides Legal Guide. All products are for laboratory research use only.